Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
39 studies found for:    celgene abi-007 | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: nab-paclitaxel IV;   Drug: CC-486
2 Recruiting Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Abraxane  (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
3 Recruiting Safety and Efficacy Study of Abraxane Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Abraxane;   Drug: Gemcitabine
4 Recruiting A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
Condition: Pancreatic Cancer
Intervention: Drug: ABI-007
5 Not yet recruiting Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubenemia
Conditions: Pancreatic Neoplasms;   Cholestasis
Interventions: Drug: nab-paclitaxel;   Drug: Gemcitabine
6 Recruiting A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Urinary Bladder Neoplasms;   Carcinoma, Transitional Cell;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Pancreatic Ductal;   Tumor Virus Infections
Interventions: Drug: CC-486 plus Carboplatin;   Drug: CC-486 plus ABI-007;   Drug: CC-486
7 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
8 Recruiting Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Conditions: Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
Interventions: Drug: nab-Paclitaxel 125 mg/m2;   Drug: gemcitabine 1000 mg/m2
9 Recruiting To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Conditions: Neuroblastoma;;   Rhabdomyosarcoma;;   Ewing's Sarcoma;;   Ewing's Tumor;;   Sarcoma, Ewing's;;   Sarcomas, Epitheliod;;   Sarcoma, Soft Tissue;;   Sarcoma, Spindle Cell;;   Melanoma;;   Malignant Melanoma;;   Clinical Oncology;;   Oncology, Medical;;   Pediatrics, Osteosarcoma;;   Osteogenic Sarcoma;;   Osteosarcoma Tumor;;   Sarcoma, Osteogenic;;   Tumors;;   Cancer;;   Neoplasia;;   Neoplasm;;   Histiocytoma;;   Fibrosarcoma;;   Dermatofibrosarcoma
Intervention: Drug: nab-paclitaxel
10 Not yet recruiting Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: nab-Paclitaxel;   Drug: Carboplatin
11 Recruiting Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Conditions: Non-Small Cell Lung Cancer;   Carcinoma;   Squamous Cell Carcinoma;   Adenocarcinoma;   Carcinoma, Large Cell;   Lung Neoplasm
Interventions: Drug: nab-paclitaxel;   Drug: Carboplatin
12 Recruiting Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Intervention: Drug: ABI-007
13 Recruiting Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007;   Drug: Gemcitabine;   Drug: simplified LV5FU2
14 Recruiting Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: ABI-007;   Drug: Ipilimumab;   Behavioral: Phone Call
15 Recruiting Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Conditions: Colorectal Cancer;   Cancer of Gastrointestinal Tract
Intervention: Drug: Abraxane
16 Recruiting Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Panitumumab;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
17 Unknown  Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Paclitaxel, nanoparticle albumin-bound
18 Recruiting Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: nab-paclitaxel
19 Recruiting The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)
Conditions: Esophageal Cancer;   Toxicity
Intervention: Drug: Nab-paclitaxel
20 Not yet recruiting Treatment With Nab-paclitaxel in Cutaneous SCC
Condition: Cutaneous Squamous Cell Carcinoma
Intervention: Drug: nab-paclitaxel

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Indicates status has not been verified in more than two years